Proliferative response of B chronic lymphocytic leukemia lymphocytes stimulated with IL2 and soluble CD23. 1994

A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
Département d'Hématologie et Oncologie Médicale, (CNRS URA 1172), CHU La Milétrie, Poitiers, France.

The in vitro proliferative response of purified B-chronic lymphocytic leukemia (B-CLL) lymphocytes cultured in the presence of soluble CD23 (sCD23) with or without IL2 was compared to the responses induced by phorbol 12-myristate 13-acetate (PMA), Staphylococcus aureus strain Cowan I (SAC), IL1, IL2, IL4, IL6 and the combination of IL2 and interferon (IFN) alpha or IFN gamma. As expected, B-CLL lymphocytes proliferated with PMA, SAC and IL2 with a clear enhancement of the IL2-induced response by IFN alpha or IFN gamma. They failed to proliferate in response to sCD23, IL1, IL4 or IL6 alone nor to the combinations of sCD23 and any of the 3 latter cytokines. However, sCD23 significantly increased the proliferation of B-CLL cells induced by IL2, suggesting a protective effect of sCD23 on apoptosis. Serum levels of sCD23 and CD23 membrane expression were high in every patient which is compatible with the hypothesis of an autocrine or paracrine activation loop. Detectable CD23 expression was lost in all cultures except for that stimulated by PMA. Only supernatants of PMA-stimulated cultures contained high sCD23 levels.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
February 2006, Clinical and laboratory haematology,
A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
October 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
January 1993, Blood cells,
A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
September 2002, Leukemia research,
A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
January 1990, Medical oncology and tumor pharmacotherapy,
A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
January 2013, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti,
A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
June 1997, Blood,
A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
March 2002, Leukemia & lymphoma,
A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
December 1996, Blood,
A Brizard, and F Morel, and J C Lecron, and B Dreyfus, and F Brizard, and A Barra, and J L Preud'homme
April 1984, Cancer genetics and cytogenetics,
Copied contents to your clipboard!